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Phase III studyAbstract Background: Lentinan (LNT) is a purified b-1, 3-glucan that augments immune re-
sponses. The present study was conducted to assess the efficacy of LNT in combination with S-
1 as a first-line treatment for unresectable or recurrent gastric cancer.
Patients and methods: Eligible patients were randomly assigned to receive S-1 alone or S-1 plus
LNT. The primary end-point was overall survival (OS). Secondary end-points were time-to-
treatment failure (TTF), overall response rate (ORR), safety, quality of life (QOL), and
biomarker. The percentages of LNT-binding monocytes in peripheral blood prior to treatment
were analysed for the biomarker assessment.
Results: One hundred and fifty-four and 155 patients were randomly assigned to receive S-1
alone or S-1 plus LNT, respectively. The median OS was 13.8 and 9.9 months (P Z 0.208),
the median TTF was 4.3 and 2.6 months (P < 0.001), the ORR was 22.3% and 18.7% for
the S-1 and S-1 plus LNT groups, respectively. The incidences of haematologic and non-hae-
matologic adverse events were similar, and no significant changes in QOL scores were
observed during the treatment in both groups. In a subpopulation of patients with LNT-
binding monocytes 2%, patients who received more than two cycles of chemotherapy showed
a longer survival time in the S-1 plus LNT group.
Conclusions: OS did not improve and TTF was significantly worse in the S-1 plus LNT group
as compared with the S-1-only group. This study showed no efficacy of LNT when combined
with S-1 treatment in patients with unresectable or recurrent gastric cancer.
Clinical trial registration ID number: UMIN 000000574.
ª 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lentinan (LNT) is a purified b-1, 3-glucan with b-1, six
branches obtained from Lentinus edodes, an edible
mushroom cultivated in Japan [1]. LNT augments im-
mune responses and increases host resistance against
murine and human tumours [2]. LNT promotes T
celledependent immunopotentiation and functions as a
maturation factor for lymphoid cells [3]. We previously
determined that the initial step of immunomodulation by
LNT may be its binding to monocytes [4]. In cancer pa-
tients, LNT-bound macrophages may produce IL-12
followed by the induction of a T helper (Th) 1 response,
which mediates cellular immunity, and may induce
downregulation of Th2 responses [5]. In patients with
advanced gastric cancer, cellular immunity is decreased
and Th2-dominant status develops [6]; so, it is important
to enhance the cellular immunity and alleviate the Th2-
dominant condition. Ochiai et al. [7]reported that an in-
crease in the number of cytotoxic T cells in peripheral
blood was found in the chemotherapy plus LNT group as
comparedwith chemotherapy-alone group in a controlled
randomised study in advanced gastric cancer.
A cooperative clinical study group in Japan has per-
formed a phase III clinical trial of LNT that revealed that
LNT prolonged survival when patients with advanced
gastric cancer were treated in combination with tegafur[8]. Recently, an individual patient data meta-analysis of
chemoimmunotherapy using LNT was performed in 650
patients with unresectable or recurrent gastric cancer in
five trials. This meta-analysis revealed that LNT signifi-
cantly prolonged the overall survival (OS) in advanced
gastric cancer patients who were treated in combination
with tegafur or other fluoropyrimidines [9]. However, all
five clinical studies included in the analysis were per-
formed in the 1980s, and S-1, which was developed in the
1990s, was not used in these trials.
S-1 was designed to enhance the anti-cancer activity
of tegafur by combining it with two modulating sub-
stances: gimeracil to inhibit dihydropyrimidine dehy-
drogenase and potassium oxonate to reduce
gastrointestinal toxicities [10]. The JCOG9912 trial,
which was designed to assess whether S-1 alone was as
good as 5-fluorouracil alone, revealed that S-1 was not
inferior to 5-fluorouracil [11]. S-1 is the most widely
used drug for the treatment of unresectable or recur-
rent gastric cancer in Japan. It is reported that the
median survival time (MST) of 400 d was in a pilot
study of S-1 combined with LNT in advance gastric
cancer [12]. It is of great interest that LNT may also
have a synergistic effect with this new type of fluo-
ropyrimidine S-1. Therefore, we conducted a rando-
mised phase III study of S-1 alone versus S-1 plus LNT
in advanced or recurrent gastric cancer to assess the
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ID 000000574).
2. Patients and methods
2.1. Patients
Eligibility criteria included histologically proven, unre-
sectable or recurrent gastric cancer; measurable lesion if
gastrectomy was performed; age20 years (no upper age
limit); an Eastern Cooperative Oncology Group perfor-
mance status (ECOG PS) of 0e2; no previous chemo-
therapy or immunotherapy; no adjuvant chemotherapy
with S-1; oral intake capability, adequate haematologic,
renal, and hepatic function; and an expected survival of
at least 3 months. Exclusion criteria were as follows:
pregnant or breast-feeding women, clinically significant
cardiovascular disease, gastrointestinal bleeding, central
nervous system metastases, and ascites and thoracic ef-
fusions necessitating paracentesis. This study was per-
formed in accordance with the principles of Good
Clinical Practice and the ethical standards laid down in
the Declaration of Helsinki. The study protocol was
approved by each site’s ethics committee, and written
informed consent was obtained from each patient.
2.2. Study design
This study was a prospective, multicentre, randomised,
open-label phase III clinical trial conducted at 97 centres
in Japan. S-1 monotherapy was selected for the control
arm because the SPIRITS trial had not finished yet
when this study started [13]. Patients were centrally
randomised to receive treatment with S-1 alone or S-1
plus LNT at a 1:1 ratio, stratified by ECOG PS (0/1
versus 2), disease status (unresectable versus recurrent),
and the institution.
2.3. Treatment
S-1 was given orally twice daily for the first 4 weeks of a
6-week cycle. The dose of S-1 administered was calcu-
lated according to the patient’s body surface area as
follows: less than 1.25 m2, 40 mg; 1.25e1.5 m2, 50 mg;
and greater than 1.5 m2, 60 mg. LNT was given as an
intravenous infusion of 2 mg/body every week. Treat-
ment for both groups was continued until one of the
following occurred: progressive disease, unacceptable
toxicity, withdrawal of consent by the patient, or
termination of treatment by the attending physician.
2.4. Efficacy and safety assessments
The primary end-point was OS, defined as time from
date of randomization to date of death from any cause.
Secondary end-points were time-to-treatment failure
(TTF), overall response rate (ORR), safety, quality oflife (QOL) score, and biomarker level. TTF was defined
as the time from randomization to treatment discon-
tinuation for any reason, including disease progression,
treatment toxicity, patient preference, physician’s deci-
sion, or death. Measurable lesions were assessed every
month during initial four cycles by computed tomog-
raphy scan according to RECIST version 1.0 [14] by
principal investigators at each participating centre until
onset of progressive disease. Adverse events were graded
according to National Cancer Institute Common Ter-
minology Criteria for Adverse Events version 3.0.
Clinical and laboratory assessments were performed at
screening and on days 1, 15, and 29 of each cycle. S-1
was withheld at grade 3 haematological toxicities or
grade 2 non-haematological toxicities and reintroduced
after recovery of toxicities at grade 1. S-1 was reduced at
any grade 3 toxicities. Treatment could be withheld for
up to 4 weeks.
2.5. QOL assessment
The self-administered, 40-item Functional Assessment
of Cancer Therapy-Biological Response Modifier [15]
was used to assess participants’ overall QOL. Patients
were asked to complete the QOL assessment at five time
points: baseline (before treatment), at 4 and 6 weeks
after treatment (during the first chemotherapy cycle)
and at 10 and 12 weeks after treatment (during the
second chemotherapy cycle). The QOL assessment was
not obligatory in this study; so, the data were collected
from the patients who agreed to participate in the QOL
assessment.
2.6. Biomarker assessment
LNT-binding monocytes were assessed by using fluo-
rescein-labelled LNT [16]. Briefly, peripheral blood ob-
tained from patients prior to the treatment was
incubated with fluorescein-labelled LNT at 37 C for
75 min, and phycoerythrin-labelled anti-CD14 antibody
(CALTAG) was added during the last 30 min. The
percentage of LNT-binding CD14þ monocytes was
measured with a fluorescence-activated cell sorter
(FACS Calibur, Becton Dickinson).
2.7. Statistical analysis
In the phase II study of S-1 treatment in patients with
advanced gastric cancer who had not received previous
chemotherapy, the MST was 244 d [17]. In a pilot study
of S-1 combined with LNT, the MST was 400 d [12]. On
the basis of these findings, we assumed MST would be 8
months in the S-1 group and 12 months in the S-1 plus
LNT group. The required number of events was esti-
mated as 284 with a 2-sided a value of 0.05 and a power
of 90% to detect differences in survival on completion of
follow-up between the S-1 and the S-1 plus LNT group.
Table 1
Patient characteristics.
S-1 (n Z 146) S-1 þ LNT (n Z 149) P
n (%) n (%)
Sex
Men 107 (73.3) 101 (67.8) 0.31
Women 39 (26.7) 48 (32.2)
Age (years)
Median (range) 74 (32e94) 73 (44e93) 0.97
ECOG PS
0 102 (69.9) 107 (71.8) 0.57
1 39 (26.7) 34 (22.8)
2 5 (3.4) 8 (5.4)
Serum albumin (g/dl)
3.0 108 (74.0) 104 (69.8) 0.04
3.0> 17 (11.6) 32 (21.5)
Unknown 21 (14.4) 13 (8.7)
Disease status
Unresectable 126 (86.3) 126 (84.6) 0.74
Recurrent 20 (13.7) 23 (15.4)
Primary lesion
Present 96 (65.8) 94 (63.1) 0.72
Resected 50 (34.2) 55 (36.9)
Measurable lesions
Yes 94 (64.4) 96 (64.4) 0.99
No 52 (35.6) 53 (35.6)
Histology
Intestinal type 57 (39.0) 76 (51.0) 0.10
Diffuse type 77 (52.8) 65 (43.6)
Unknown 12 (8.2) 8 (5.4)
LNT, lentinan; ECOG PS, Eastern Cooperative Oncology Group
performance status.
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using Pearson’s chi-square test, except for age, which was
compared by using ManneWhitney’s U test. OS and
TTF were compared by using log-rank tests stratified by
randomization factors and KaplaneMeier estimates.
Cox proportional hazards models stratified by the
randomization factors estimated hazard ratios (HRs)
and 95% confidence intervals (CIs). For the biomarker
assessment, we performed the weighted log-rank test
with the HarringtoneFleming class of weights [18]. P
values less than 0.05 were considered statistically signif-
icant. Statistical analyses were performed by using SAS
version 9.2 and version 9.4 (SAS Institute, Cary, NC).
3. Results
3.1. Patients and treatment exposure
Between February 2007 and June 2010, 309 patients were
enrolled (Fig. 1). Fourteen patients were excluded from
the analysis; so, the full analysis set comprised 295 pa-
tients, and OS was analysed in these patients. Six patients
were excluded from the full analysis set population. The
safety population comprised 289 patients, and the safety,
response, TTF, and QOL were analysed in this safety
population. Table 1 shows baseline patient characteris-
tics, which were well balanced between the treatment
groups. However, the proportion of patients with serum
albumin less than 3.0 g/dl was significantly higher in the
S-1 plus LNT group as compared to the S-1 group,309 patients enrolled
Assigned to S-1
(n=154) 
Safety population
(n=142) 
Safety population
(n=147) 
Full Analysis Set 
(n=146)
Full Analysis Set 
(n=149)
8 patients excluded
5 no measurable lesion after gastrectomy
1 previous chemotherapy
1 double cancers
1 concurrent immunotherapy
6 patients excluded
2 no measurable lesion after gastrectomy
1 previous chemotherapy
1 gastrointestinal bleeding
1 treatment start before registration
1 no case report form
4 patients excluded
3 not treated
1 unknown treatment situation  
2 patients excluded
2 not treated
Assigned to S-1+LNT
(n=155) 
Fig. 1. CONSORT diagram.
Table 2
Haematologic and non-haematologic adverse events.
S-1 (n Z 142) S-1 þ LNT
(n Z 147)
All grades,
n (%)
Grade 3 or
4, n (%)
All grades,
n (%)
Grade 3
or 4, n (%)
Leucopenia 65 (45.8) 6 (4.2) 69 (46.9) 12 (8.2)
Neutropenia 73 (51.4) 17 (12.0) 68 (46.3) 16 (10.9)
Anaemia 72 (50.7) 7 (4.9) 75 (51.0) 12 (8.2)
Thrombocytopaenia 63 (44.4) 1 (0.7) 64 (46.3) 6 (4.1)
Febrile neutropenia 1 (0.7) 1 (0.7) 0 0
Anorexia 52 (36.6) 12 (8.5) 75 (51.0) 19 (12.9)
Nausea 22 (15.5) 0 35 (23.8) 5 (3.4)
Vomiting 14 (9.9) 1 (0.7) 19 (12.9) 2 (1.4)
Diarrhoea 24 (16.9) 1 (0.7) 28 (19.0) 6 (4.1)
Fatigue 43 (30.3) 5 (3.5) 52 (35.4) 13 (8.8)
Stomatitis 24 (16.9) 1 (0.7) 28 (19.0) 3 (2.0)
Pigmentation 36 (25.4) 0 38 (25.9) 0
Rash 0 0 3 (2.0) 1 (0.7)
Lacrimation 18 (12.7) 4 (2.8) 14 (9.5) 0
Handefoot syndrome 12 (8.5) 1 (0.7) 11 (7.5) 0
Creatinine elevation 17 (12.0) 0 14 (9.5) 1 (0.7)
Hyponatremia 31 (21.8) 7 (4.9) 27 (18.4) 7 (4.8)
LNT, lentinan.
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Patients in the S-1 group received a median of three
cycles of S-1 (range, 1e38), and patients in the S-1 plus
LNT group received a median of two cycles of S-1
(range, 1e19) and 22 treatments with LNT (range,
1e104). In the S-1 group, the S-1 doses were reduced in
17.8% of patients. In the S-1 plus LNT group, 19.5% of
patients had dose reductions.
3.2. Efficacy
All follow-up assessments were completed by 30th
June 2012, which was 48 months after the enrolment of
the last patient. The median OS was 13.8 months (95%
CI, 11.8e15.8) and 9.9 months (95% CI, 7.9e12.0) for
the S-1 group and S-1 plus LNT group, respectively,
with an HR of 1.169 (95% CI, 0.916e1.493, PZ 0.208)
(Fig. 2).
The reasons for treatment discontinuation are pro-
gressive disease in 79 and 74 patients, clinical non-
efficacy in 8 and 15 patients, adverse events in 18 and 29
patients, withdrew consent in 15 and 13 patients, in-
dications for surgery in 2 and 3 patients, death in 2 and 4
patients, and others in 16 and 10 patients in the S-1
group and the S-1 plus LNT group, respectively. Me-
dian TTF was 4.3 months (95% CI, 3.8e4.7) and 2.6
months (95% CI, 2.2e3.0) for the S-1 group and S-1 plus
LNT group, respectively, with an HR of 1.540 (95% CI,
1.210e1.961, P < 0.001) (Fig. 2).
Objective response was evaluable by the investigators
in the 190 patients (65.7%) with measurable disease at
baseline. The ORR was 22.3% in the S-1 group
including complete response (CR) in one patient and
partial response (PR) in 19 patients. The ORR was
18.7% in the S-1 plus LNT group including CR in oneytil ibabor
P
S
Of o
Months
S-1             146    13.8M
S-1 + LNT  149      9.9M    1.17 (0.92-1.50)    0.208  
n Median    HR (95% CI)          P
A
Number at risk
S-1             146   113    80     46     31    14       7       4       3       0       0          
S-1 + LNT  149   108    59     40     25      8       6       3       3       2       1
Nu
S-
S-
Fig. 2. KaplaneMeier curves for OS in the full analysis set population
time-to-treatment failure; LNT, lentinan; HR, hazard ratio; CI, confidpatient and PR in 17 patients. There was no statistical
difference in the ORR between the two groups.3.3. Safety
The incidence of adverse events during treatment is
summarised in Table 2. The incidences of haematologic
and non-haematologic adverse events were similar in
both groups. Only one patient died as a result of neu-
tropenia related to protocol treatment in the S-1 plus
LNT group. The proportions of patients who termi-
nated treatment because of intolerable adverse eventsP
ro
ba
bi
lit
y
of
 T
TF
S-1             142      4.3M
S-1 + LNT  147      2.6M    1.54 (1.21-1.96)    <0.001 
n Median    HR (95% CI)          P
Months
B
mber at risk
1             142   38     13       5       2       2       1       1       1           
1 + LNT  147     27       5       2       1       0       0       0       0 
(A) and TTF in safety population (B). OS, overall survival; TTF,
ence interval.
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1 plus LNT group.
3.4. QOL analysis
One hundred and nine (76.8%) patients in the S-1 group
and 117 (79.6%) patients in the S-1 plus LNT group
completed a baseline QOL assessment. Fig. 3 shows the
baseline scores and changes in the mean scores for the
overall QOL scale of each group. No significant changes
were observed at 4, 6, 10, and 12 weeks after chemo-
therapy as compared with baseline in both the S-1 and
S-1 plus LNT groups.
3.5. Biomarker assessment
The percentages of LNT-binding cells in total CD14þ
monocytes showed individual variations ranging from
0.03% to 38.7% (median, 2.0%) among 309 patients.
Patients were divided into an LNT high-binding popu-
lation with at least 2.0% of monocytes bound to LNT
and an LNT low-binding population with less than 2.0%
of monocytes bound to LNT.
In patients who received more than two cycles of
chemotherapy, OS was similar in both the S-1 and S-1
plus LNT groups in the LNT low-binding population.
However, in the LNT high-binding population, some
patients showed a longer survival time in the S-1 plus
LNT group as compared to the S-1 group. The 3-year
survival rate of the S-1 group was 3.1%, whereas that of
the S-1 plus LNT group was 24.1%. A longer OS was
observed in the S-1 plus LNT group as compared to theQ
O
L 
sc
or
e
Pre-treatment 4W
Number of patients
S-1                                        109                  102                
S-1 + LNT                             117                  101                
Fig. 3. Changes in QOL score during treatment. QOL was assessed
expressed as mean  standard deviation. QOL, quality of life; FA
Response Modifier; LNT, lentinan.S-1 group (HarringtoneFleming method, r1 Z 0 and
r2Z 0.5, PZ 0.0491; r1Z 0 and r2Z 1, PZ 0.0171)
(Fig. 4).4. Discussion
This study showed no efficacy of LNT administration
combined with S-1 treatment in patients with unresect-
able or recurrent gastric cancer. OS did not improve in
the S-1 plus LNT group as compared with the S-1-only
group. However, TTF was significantly worse in the S-1
plus LNT group. Although the patient characteristics
were well balanced between the groups, the proportion
of patients with low serum albumin was significantly
higher in the S-1 plus LNT group. Hypoalbuminemia is
an independent prognostic factor for OS in patients with
advanced gastric cancer who receive chemotherapy
[19,20]. Therefore, it is speculated that the unexpected
high proportion of enrolment of patients with hypo-
albuminemia in the S-1 plus LNT group caused the
worse TTF as compared to the S-1 group.
In the present study, MST was 13.5 months in the S-1
group and 10.9 months in the S-1 plus LNT group,
respectively. In previous phase III clinical trials in pa-
tients with advanced gastric cancer, the median survival
of 10.5, 11.0, and 11.4 months was reported for S-1
treatment by Narahara et al. [21], Koizumi et al. [13],
and Boku et al. [11], respectively. The MST for S-1
treatment in our study was almost the same as those in
these three previous studies. However, patients analysed
in these three studies were 75 years of age or younger.
According to the Surveillance, Epidemiology, and EndS-1             
S-1 + LNT
6W 10W 12W
   104                     84               78
     93                     63                   62  
by FACT-BRM. Maximum score is 160 points, and values are
CT-BRM, Functional Assessment of Cancer Therapy-Biological
ytilibabor
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S-1              64     54     39      22    15      8       3        3       3           
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Number at risk
S-1              44     39     30     16       9      3       1       0 0       0       0    
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Fig. 4. KaplaneMeier curves of OS according to the percentages of LNT-binding monocytes in patients who received more than two
cycles of treatment. OS in LNT low-binding population (A) and LNT high-binding population (B). The weighted log-rank test with the
HarringtoneFleming class of weights were performed in LNT high-binding population and resulted in, r1Z 0 and r2Z 0.5, PZ 0.0491;
r1 Z 0 and r2 Z 1, P Z 0.0171. OS, overall survival; LNT, lentinan.
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35.7% of patients with gastric cancer were diagnosed
over 75 years of age. Half of the patients enrolled in this
study were over the age of 73; so, the efficacy of S-1
treatment for elderly patients with gastric cancer could
be suggested in this study.
QOL is impaired in patients with advanced gastric
cancer [23]; so, it is important to maintain the QOL
during the cancer treatment. An improvement of QOL
was showed in patients with gastric cancer who
received chemotherapy [24]. However, some authors
reported no improvement of QOL during cancer
treatment [25,26]. No significant changes were observed
during treatment with either S-1 alone or S-1 plus LNT
as compared with before treatment. LNT had no effi-
cacy to improve the QOL in patients with advanced
gastric cancer.
LNT-binding monocytes were analysed for the
biomarker assessment. In the LNT high-binding pop-
ulation, patients who received more than two cycles of
chemotherapy showed a longer survival time in the S-1
plus LNT group as compared with in the S-1 group. In
chemotherapy, it is important to select patients who are
promising candidates for responding to treatment.
Hazama et al. [27] reported the importance of
biomarker exploration for selecting patients with a
better treatment outcome in chemotherapy with vac-
cine treatment for advanced colorectal cancer. The
percentages of LNT-binding monocytes could be one
of the biomarker for predicting the long survivors in
patients with advanced gastric cancer who received S-1
treatment with LNT.
In conclusion, the present study showed no efficacy of
LNT administration combined with S-1 treatment in
patients with unresectable or recurrent gastric cancer.Disclosure
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